{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:17:26Z","timestamp":1793985446242,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jaci.2024.07.029","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T18:41:41Z","timestamp":1724524901000},"page":"1500-1510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study"],"prefix":"10.1016","volume":"154","author":[{"given":"Eugene","family":"Bleecker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Blaiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby","family":"Jacob-Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Nag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Borsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.07.029_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40413-018-0192-5","article-title":"Type 2 immunity in asthma","volume":"11","author":"Caminati","year":"2018","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2024.07.029_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00013-2018","article-title":"Understanding asthma phenotypes: the World Asthma Phenotypes (WASP) international collaboration","volume":"4","author":"Pembrey","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaci.2024.07.029_bib5","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.07.029_bib6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/187221307782418900","article-title":"A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma","volume":"1","author":"D\u2019Amato","year":"2007","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"10.1016\/j.jaci.2024.07.029_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2024.07.029_bib8","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.07.029_bib11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S2213-2600(18)30291-1","article-title":"Urgent need for pragmatic trial platforms in severe asthma","volume":"6","author":"Pilette","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2024.07.029_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/13696998.2022.2074195","article-title":"Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison","volume":"25","author":"Menzies-Gow","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.jaci.2024.07.029_bib13","article-title":"Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma","volume":"191","author":"Bateman","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2024.07.029_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00306-2021","article-title":"Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma","volume":"7","author":"Praetorius","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaci.2024.07.029_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.jaci.2024.07.029_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/JAA.S189676","article-title":"Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study","volume":"12","author":"Llanos","year":"2019","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2024.07.029_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jaci.2024.07.029_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000097025","article-title":"Reference values of total serum IgE and their significance in the diagnosis of allergy in young European adults","volume":"142","author":"Carosso","year":"2007","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.07.029_bib20","article-title":"Broader impact of IL-4Ra blockade than IL-5 blockade on type 2 inflammation","volume":"54","author":"Allinne","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2024.07.029_bib21","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1067\/mai.2003.1527","article-title":"Inhibition of the IL-4\/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma","volume":"111","author":"Hahn","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.029_bib22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.anai.2022.06.012","article-title":"Biologic use and outcomes among adults with severe asthma treated by US subspecialists","volume":"129","author":"Panettieri","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2024.07.029_bib23","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2023.01.020","article-title":"Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: a target trial emulation","volume":"151","author":"Akenroye","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.07.029_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100726","article-title":"Systemic corticosteroids in asthma: a call to action from World Allergy Organization and Respiratory Effectiveness Group","volume":"15","author":"Bleecker","year":"2022","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2024.07.029_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2024.07.029_bib26","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/sim.3854","article-title":"The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies","volume":"29","author":"Austin","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.jaci.2024.07.029_bib27","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1097\/MLR.0b013e31806518ac","article-title":"Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases","volume":"45","author":"Curtis","year":"2007","journal-title":"Med Care"},{"key":"10.1016\/j.jaci.2024.07.029_bib28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924008650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924008650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T12:40:48Z","timestamp":1733316048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924008650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0091674924008650"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.07.029","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}